Johannes BrÃ¤gelmann

List of Publications by Year
in descending order

Version: 2024-02-01

44 papers	2,835 citations	304743 22 h-index	265206 42 g-index
45 all docs	45 docs citations	45 times ranked	5996 citing authors

#	Article	IF	Citations
1	Inhibition of Cyclin-Dependent Kinase 8/Cyclin-Dependent Kinase 19 Suppresses ItsÂPro-Oncogenic Effects in Prostate Cancer. American Journal of Pathology, 2022, 192, 813-823.	3.8	4
2	Histone Demethylase KDM5C Drives Prostate Cancer Progression by Promoting EMT. Cancers, 2022, 14, 1894.	3.7	6
3	CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization. Molecular Cancer Therapeutics, 2022, 21, 821-830.	4.1	4
4	Normics: Proteomic Normalization by Variance and Data-Inherent Correlation Structure. Molecular and Cellular Proteomics, 2022, 21, 100269.	3.8	2
5	Epigenomeâ€Wide Analysis of Methylation Changes in the Sequence of Gallstone Disease, Dysplasia, and Gallbladder Cancer. Hepatology, 2021, 73, 2293-2310.	7.3	24
6	MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I. Nature Communications, 2021, 12, 5505.	12.8	30
7	CDK19 as a diagnostic marker for high-grade prostatic intraepithelial neoplasia. Human Pathology, 2021, 117, 60-67.	2.0	3
8	Recurrent HNSCC Harbor an Immunosuppressive Tumor Immune Microenvironment Suggesting Successful Tumor Immune Evasion. Clinical Cancer Research, 2021, 27, 632-644.	7.0	49
9	Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer. Npj Precision Oncology, 2021, 5, 102.	5.4	11
10	Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer. International Journal of Cancer, 2020, 146, 577-588.	5.1	23
11	CDK19 as a Potential HPV-Independent Biomarker for Recurrent Disease in HNSCC. International Journal of Molecular Sciences, 2020, 21, 5508.	4.1	6
12	A comparative analysis of cell-type adjustment methods for epigenome-wide association studies based on simulated and real data sets. Briefings in Bioinformatics, 2019, 20, 2055-2065.	6.5	15
13	MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer. Nature Communications, 2019, 10, 3485.	12.8	54
14	Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer. JCO Precision Oncology, 2019, 3, 1-14.	3.0	17
15	K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways. Journal of Thoracic Oncology, 2019, 14, 606-616.	1.1	178
16	Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients. Clinical Cancer Research, 2018, 24, 1337-1343.	7.0	71
17	Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. Nature Communications, 2018, 9, 4655.	12.8	107
18	Abstract 1920: Targeting structural RET and MET kinase alterations in lung adenocarcinoma patients. , 2018, , .		0

#	Article	IF	Citations
19	Abstract IA27: MYC drives molecular and therapeutically distinct subtype of SCLC. , 2018, , .		0
20	MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. Cancer Cell, 2017, 31, 270-285.	16.8	406
21	Mechanisms of Primary Drug Resistance in FGFR1-Amplified Lung Cancer. Clinical Cancer Research, 2017, 23, 5527-5536.	7.0	44
22	Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. Science Translational Medicine, 2017, 9, .	12.4	55
23	Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma. Cell Reports, 2017, 20, 2833-2845.	6.4	40
24	Family matters: How MYC family oncogenes impact small cell lung cancer. Cell Cycle, 2017, 16, 1489-1498.	2.6	75
25	FirebrowseR: an R client to the Broad Instituteâ€™s Firehose Pipeline. Database: the Journal of Biological Databases and Curation, 2017, 2017, baw160.	3.0	144
26	Pan-Cancer Analysis of the Mediator Complex Transcriptome Identifies CDK19 and CDK8 as Therapeutic Targets in Advanced Prostate Cancer. Clinical Cancer Research, 2017, 23, 1829-1840.	7.0	74
27	Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression. International Journal of Molecular Sciences, 2017, 18, 7.	4.1	36
28	Mediator Complex Subunit MED1 Protein Expression Is Decreased during Bladder Cancer Progression. Frontiers in Medicine, 2017, 4, 30.	2.6	13
29	PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma. Oncotarget, 2017, 8, 52889-52900.	1.8	82
30	MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy. Oncotarget, 2017, 8, 14719-14735.	1.8	21
31	Exanthem subitum (human herpesvirus-6 reactivation) after autologous stem cell transplantation. Transplant Infectious Disease, 2016, 18, 255-256.	1.7	3
32	Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma. Targeted Oncology, 2016, 11, 631-642.	3.6	10
33	Targeting DDR2 in head and neck squamous cell carcinoma with dasatinib. International Journal of Cancer, 2016, 139, 2359-2369.	5.1	27
34	Web-TCGA: an online platform for integrated analysis of molecular cancer data sets. BMC Bioinformatics, 2016, 17, 72.	2.6	140
35	Comprehensive analysis of the transcriptional profile of the Mediator complex across human cancer types. Oncotarget, 2016, 7, 23043-23055.	1.8	24
36	MERTK as a novel therapeutic target in head and neck cancer. Oncotarget, 2016, 7, 32678-32694.	1.8	17

#	Article	IF	Citations
37	Differential expression of Mediator complex subunit MED15 in testicular germ cell tumors. Diagnostic Pathology, 2015, 10, 165.	2.0	11
38	Performance of the CHARGE-AF risk model for incident atrial fibrillation in the EPIC Norfolk cohort. European Journal of Preventive Cardiology, 2015, 22, 932-939.	1.8	57
39	Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes. Clinical Cancer Research, 2015, 21, 870-881.	7.0	303
40	Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma. Oral Oncology, 2015, 51, 53-58.	1.5	26
41	Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas. Clinical Cancer Research, 2015, 21, 632-641.	7.0	525
42	Comparison of two large, genetically and clinically annotated head and neck cancer (HNC) cohorts (TCGA, CHGC) and differential treatment effects on TP53 mutated, as well as oral cavity cancers.. Journal of Clinical Oncology, 2015, 33, 6080-6080.	1.6	0
43	Plasma vitamin C and risk of hospitalisation with diagnosis of atrial fibrillation in men and women in EPIC-Norfolk prospective study. International Journal of Cardiology, 2014, 177, 830-835.	1.7	14
44	RON(MST1R)is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biology and Therapy, 2011, 12, 9-46.	3.4	79